The Treatment: XYWAV is an FDA-approved treatment for narcolepsy and Idiopathic Hypersomnia (IH).

Study Aims: Assess the safety and efficacy of the treatment on sleepiness, polysomnography measurements (eg, sleep stage transitions, sleep patterns, and sleep quality), daytime and nighttime symptoms, pharmacokinetics (in narcolepsy), and patient-reported outcomes including subjective sleep quality and quality of life in patients with IH or narcolepsy.

Trial Duration: 10-36 weeks

Inclusion Criteria (simplified):

  • 18 to 75 years old
  • Has a primary diagnosis of IH or narcolepsy (Type 1 or Type 2)

Link to the trial registration

Disclaimer: The information provided in this blog post is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider for recommendations specific to your individual health needs.